Outstanding Service Award in Obstetrics Archives

🌱EARLY ACADEMIC PURSUITS

Dr. Yu Kang obtained his PhD and completed his postdoctoral fellowship at MD Anderson Cancer Research Center, which laid a strong foundation for his research in gynecologic oncology. His early education focused on the mechanisms of cancer biology and treatment modalities, establishing a profound understanding of the complexities of gynecologic tumors.

Currently serving as the chief physician at the Obstetrics & Gynecology Hospital of Fudan University, Dr. Kang is also a doctoral supervisor. His clinical practice centers around individualized precision treatment and prevention strategies for gynecologic tumors, ensuring that patients receive the most effective therapies tailored to their specific needs.

Dr. Kang’s main research focus includes ovarian cancer, PJ syndrome, and hereditary breast and ovarian cancer (HBOC). He has published extensively in prestigious journals such as JNCI, contributing significantly to the understanding and treatment of rare gynecological tumors. His research has led to the publication of 32 SCI articles, the acquisition of 4 national patents, and the authorship of 12 monographs.

While specific citation metrics are not provided, Dr. Kang’s prolific output of 53 journal publications in SCI and Scopus-indexed journals underscores his impact in the academic community and highlights the significance of his research findings in advancing gynecologic cancer treatment.

Through his research and clinical practice, Dr. Kang has made significant strides in the field of gynecologic oncology, particularly in precision medicine. His collaborative efforts with organizations such as the MD Anderson Cancer Center Sister Organization Network Foundation have further advanced the potential treatment options for epithelial ovarian cancer, showcasing his commitment to improving patient outcomes.

Dr. Kang’s ongoing work in the field of gynecologic tumors aims to pave the way for innovative treatment modalities and improved patient care. With several patents in process and an active editorial role in Gynecologic Oncology, he is poised to continue influencing the field significantly. His commitment to research and patient care ensures a lasting legacy in gynecologic oncology.

MRI grading for informed clinical decision-making in Peutz–Jeghers syndrome patients with cervical lesions
Authors: Jiang, A., Chen, Y., Ning, Y., Xu, C., Kang, Y.
Journal: Scientific Reports, 2024, 14(1), 23731
Clinical characteristics and status of treatment of small-cell carcinoma of the ovary, hypercalcemic type in the Chinese population: a meta-analysis
Authors: Zheng, K., Gao, Y., Xu, C., Kang, Y.
Journal: Journal of Gynecologic Oncology, 2024, 35(4), e96
Immunotherapy combined with targeted therapy in advanced small cell carcinoma of the ovary of hypercalcemic type: A case of overall survival lasting for over 5 years
Authors: Gao, Y., Zang, L., Ye, Y., Wang, H., Xu, C., Kang, Y.
Journal: European Journal of Obstetrics and Gynecology and Reproductive Biology, 2024, 297, pp. 270–274
Correction to: Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer
Authors: Li, K., Xu, J., Wang, J., Wu, S., Kang, Y.
Journal: Cancer Immunology, Immunotherapy, 2024, 73(6), 105
Do survivors of borderline ovarian tumors have susceptibility to secondary primary malignancies? A SEER population-based study
Authors: Wang, J., Du, Y., Kang, Y.
Journal: International Journal of Gynecology and Obstetrics, 2024, 165(3), pp. 1229–1236